KEYWORDS: all-trans-retinoic acid, time-dependent elimination, pharmacokinetic model, rat, intravenous administration, oral administration The time-dependent elimination kinetics of all-transretinoic acid (ATRA) has been associated with autoinduction of its metabolism and has led to the hypothesis that rapid development of acquired clinical resistance to ATRA may be prevented by coadministration of metabolic inhibitors. This study in rats was performed to investigate the pharmacokinetics and onset of timedependent elimination of ATRA, with the purpose of establishing an animal model suitable for in vivo preclinical studies of compounds capable of inhibiting ATRA metabolism. After the intravenous (IV) bolus administration of single doses of ATRA (1.60 mg kg ), the plasma concentration-time curves showed an accelerated decline at 180 minutes after dosing. The plasma clearance (Cl) of ATRA, determined after IV administration of a second dose (1.60 mg kg -1 ), at 180 minutes was greater than Cl after a single dose, thus indicating the existence of a time-dependent elimination process detectable 180 minutes after administration of the first dose. Such time-dependent elimination was confirmed by means of an IV constant-rate infusion of 0.48 mg h -1 kg -1 of ATRA during 10 hours. Peak plasma ATRA concentration was achieved at 180 minutes, after which the plasma concentration decreased to reach a much lower apparent steady-state drug concentration at 420 minutes. The area under the plasma concentration-time curve (AUC) obtained after oral administration of a second ATRA dose (1.60 mg kg -1 ) was ~8% of the AUC obtained after a single oral dose; consistent with a time-dependent increase in the elimination of ATRA, as was observed after IV administration.
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INTRODUCTION
All-trans-retinoic acid (ATRA) is effective for inducing remission in patients with acute promyelocytic leukemia (APL) [1] [2] [3] [4] and attention has recently also focused on its potential for treating solid tumors. [5] [6] [7] [8] [9] Detailed analysis of the pharmacokinetic behavior of ATRA in humans has been restricted by the low plasma concentration reached after an oral dose and the absence of an IV form, which would avoid the variability associated with oral drug administration. Despite these limitations, some pharmacokinetic studies in humans have demonstrated a complex pharmacokinetic behavior of ATRA, suggesting that its elimination is dose dependent and capacity limited. Pharmacokinetic studies of chronic daily dosing schedule have reported a dramatic decrease in systemic exposure to ATRA over time (time-dependent elimination), as measured by the area under the plasma concentration-time curve (AUC). [10] [11] [12] The observed progressive decrease in plasma AUC values with continued oral therapy has been related to the induction of drug catabolism by cytochrome P450 (CYP) enzymes and has led to the hypothesis that the rapid development of acquired clinical resistance to ATRA in patients with APL may have a pharmacokinetic basis, resulting in an inability to present an effective drug concentration to the leukemia cells during continuous treatment. 12 Nevertheless, recent studies also suggest that molecular disturbances in APL cells could play a predominant role in the mechanism of ATRA resistance, particularly if disease relapse occurs a few months after discontinuing ATRA therapy. potential metabolic inhibitors upon the plasma concentrations of ATRA requires an animal model reflecting the pharmacokinetic features of ATRA observed in humans. Accordingly, the aim of the present study was to characterize the pharmacokinetics of ATRA in rats, with a special focus on the onset of time-dependent elimination. ATRA was administered intravenously (IV), as a bolus injection and as a constant-rate infusion, and also orally-the latter being the usual administration route in humans.
MATERIALS AND METHODS

Methods
Animals
Male Wistar rats weighing 295 to 325 g (mean 310 g) were used throughout the study, and the experiments were performed in accordance with our institutional rules for the use of animals in research. Animals were maintained under a 12:12-hour light/dark cycle and had free access to food and water before the experiments. On the day before drug administration, animals were placed under ether anesthesia and subjected to cannulation of the right jugular vein with medical-grade silicone tubing (Silclear, Degania Silicone Ltd, Degania Bet, Israel; inner diameter, 0.5 mm; outer diameter, 0.94 mm) to facilitate blood sampling and IV administration.
14 Oral doses were administered by gastric intubation under light ether anesthesia. Some rats were cannulated in the left jugular vein, and this cannula was used for constantrate infusion of ATRA, whereas blood sampling was performed through the right jugular vein cannula. Following the operation, the animals were placed in individual cages and were fasted overnight, with free access to water, for 12 to 14 hours prior to the experiments. After ATRA dosing or the start of constant-rate infusion, blood samples (0.2-0.3 mL) were collected at fixed times with heparinized syringes. After each sampling, blood volume was replaced with the same volume of saline. Plasma was immediately separated from erythrocytes by centrifugation (1000 g for 5 minutes), processed as indicated below, and stored at -20°C until analysis by high-performance liquid chromatography (HPLC).
Experiments
A reserve solution of ATRA (4 mg mL -1 ) was prepared as follows: 20 mg of ATRA and 0.7 mL of 0.1 N NaOH were added to a mixture of ethanol (3.5 mL) and Tween 80 (500 mg). The mixture was subjected to ultrasound for 3 minutes, and the volume was completed up to 5 mL with distilled water. This solution was stored at -30°C. The dosing solutions of ATRA were prepared immediately before administration by diluting an aliquot of the reserve solution as indicated below. All recipients containing ATRA solutions were covered with aluminum foil to protect ATRA from light. Seven groups of rats (n = 6 each) were administered ATRA as indicated in Table 1 .
Administration of a Single Dose of ATRA A 0.5-mL aliquot of ATRA solution (1 mg mL -1 , groups 1 and 3; 0.25 mg mL -1 , groups 2 and 4) prepared by dilution of the reserve solution with saline was administered to the rats via the IV and the oral routes (as indicated in Table 1 ). Blood samples were collected at fixed times until 240 minutes after dosing.
Administration of 2 Consecutive Doses of ATRA Rats of groups 5 and 6 received 2 consecutive doses of 1.60 mg kg -1 of ATRA (0.5 mL of a 1 mg mL -1 solution) IV and orally, respectively. After IV administration of the first dose (group 5), 3 blood samples were taken (at 60, 120, and 180 minutes), and the second IV dose was administered at 180 minutes. Additional blood samples were collected until 180 minutes after administration of the second dose. In the case of oral administration (group 6), 4 blood samples were taken (60, 120, 180, and 240 minutes) after administration of the first dose; the second dose was then administered (at 240 minutes), and blood samples were collected for an additional period of 90 minutes.
Constant-Rate Infusion of ATRA For the IV constant-rate infusion of ATRA (group 7), a dosing solution of ATRA (0.2 mg mL -1 ) was prepared by diluting 0.5 mL of the reserve solution of ATRA with 9.4 mL of saline and 0.1 mL of 0.1 N NaOH. This small amount of NaOH was added to avoid ATRA precipitation from the dosing solution during the infusion period (10 hours). The dosing solution was infused IV at 0.75 mL h -1 (0.48 mg h -1 kg
) through the left jugular vein during 10 hours, and blood samples were collected through the cannula implanted in the right jugular vein. At the end of the infusion period, an aliquot of the administration solution was analyzed and no significant degradation of ATRA was detected.
Analytical Method
All samples were analyzed for ATRA concentration by reversed-phase HPLC. The HPLC equipment consisted of a Waters 515 pump, a Waters 486 UV detector (Ȝ = 340 nm), and a Waters 743 integrator (Waters Corp, Milford, MA), and a Rheodyne 7725i injector (Rheodyne, Cotati, CA). The column was a Nova Pak C 18 (Waters) cartridge (15 cm × 3.9 mm, inner diameter), and the mobile phase was a mixture of acetate buffer (100mM, pH 5) and acetonitrile (20:80, vol/vol) delivered at a flow rate of 1 mL min -1 . Prior to injection into the chromatograph, plasma samples were subjected to the following extraction method: 100 μL of acetonitrile was added to 100 μL of plasma sample and the mixture was shaken by hand (for 10 seconds), placed in the refrigerator (-4°C for 10 minutes), and centrifuged (2000 g for 5 minutes). The supernatant was transferred to a clean tube and stored at -20°C until injection (25 μL) into the chromatograph.
Calibration graphs were constructed by linear leastsquares regression analysis of the plot of the peak height against the concentration of ATRA in 6 standards covering the range of 30 to 1000 ng mL -1 , which were prepared by spiking blank plasma with ATRA. The concentration of ATRA in plasma samples was determined by interpolation in the calibration graph of the corresponding peak-height value obtained in the chromatograms.
Samples expected to contain a ATRA concentration greater than 1000 ng mL -1 were diluted appropriately with blank plasma before analysis. Three control standards (100, 500, and 1000 ng mL -1 ) were used to evaluate the precision of the method, which was estimated to be better than 5%. The detection limit (~10 ng mL -1 ) was estimated as the ATRA concentration in plasma samples yielding a peak height 3 times greater than the noise level. The lowest concentration used for the calibration graph (30 ng mL -1 ) was used as the lower limit of quantification.
Materials
ATRA, NaOH, ethanol, Tween 80, diethyl ether, and acetic acid (used to prepare acetate buffer) were purchased from Guinama (Valencia, Spain). Acetonitrile of HPLC grade was purchased from Panreac (Barcelona, Spain), and heparin was purchased from Leo laboratories (Madrid, Spain).
Pharmacokinetic Methods and Statistics
Pharmacokinetic parameters of ATRA in each experimental group were estimated from the corresponding concentration-time curves by noncompartmental analysis. The total AUC was calculated by means of a combination of the regular trapezoidal and the logarithmic trapezoidal rules. 15 The terminal disposition half-life (t 1/2 ), the steady-state volume of distribution (Vd ss ), and the plasma clearance (Cl) were calculated by the usual procedures. 16 The maximum plasma concentration reached after drug administration (C max ) and the time at which it was reached (T max ) were observed values.
A 2-compartment pharmacokinetic model with timedependent drug elimination was fitted to plasma concentrations of ATRA obtained after IV administration (groups 1, 2, 5, and 7) by means of nonlinear leastsquares regression using WinNonLin software (Pharsight Corporation, Palo Alto, CA). 17 In that model, it is assumed that plasma clearance of the drug increases with time until a maximum value is reached, and that there is a time delay between drug administration and the onset of time-dependent elimination. The equations describing the model are as follows:
where C is the plasma concentration of the drug; t is the time elapsed from bolus administration or start of infusion; P is the "concentration" of drug in the peripheral compartment (strictly speaking, it represents the ratio between drug amount in the peripheral compartment and central compartment volume); k 12 is the first-order rate constant for drug transfer from central compartment to peripheral compartment; k 21 is the first-order rate constant for drug transfer from peripheral compartment to central compartment; Vc is the volume of distribution of the central compartment; 2480 is infusion rate in ng min
; T lag is the time delay from drug administration and the onset of time-dependent elimination; Cl 0 is the initial plasma clearance; Cl max is the maximum plasma clearance; and ClT 50 is the time elapsed from T lag at which the plasma clearance is 50% of Cl max .
Statistical comparisons were performed via Student t test or Mann-Whitney U test, depending on the homogeneity or nonhomogeneity of variance, respectively (checked by means of Snedecor F test). 18 Statistical significance was accepted at P <.05.
RESULTS
Single-Dose Studies
Plasma levels of ATRA after IV administration showed a poly-exponential profile for both single doses ( Figure  1) . After administration of the higher dose (1.60 mg kg -1 ), the plasma level-time curve exhibited 2 phases (biexponential decline) characteristic of a 2-compart ment pharmacokinetic model, although ~180 minutes after dosing, an accelerated decline or third-phase was observed in the plasma curve. This type of plasma leveltime profile could suggest a saturable, or capacitylimited, elimination of ATRA. According to this interpretation, plasma levels exceeding ~400 ng mL -1 (plasma concentration at 180 minutes after dosing) would provoke a certain degree of saturation of the capacity-limited elimination process, whereas plasma levels lower than 400 ng mL -1 would give rise to apparent first-order kinetics. Such apparent concentrationdependent kinetics should also be evident as dosedependent kinetics; however, the administration of a 4-fold lower dose of ATRA (0.40 mg kg -1
) gave rise to a plasma level-time curve with a similar profile, which was practically parallel to that obtained with the highest dose (Figure 1) . The ATRA plasma concentration at 30 minutes after administration of the 0.40 mg kg -1 dose was lower than 400 ng mL -1 ; however, the slope of the curve from 30 to 90 minutes was similar to the slope of the second phase of the 1.60 mg kg -1 dose curve rather than to the slope of the third phase, as would be expected if concentration-dependent kinetics was involved. At 120 minutes after dosing, a third phase parallel to the third phase of the 1.60 mg kg -1 dose was observed. The ATRA t 1/2 was determined in this third phase, and practically the same value was obtained for both doses ( Table 2 ). The Cl of ATRA was also similar for both doses, which indicates that ATRA elimination is not capacity limited in this range of doses. Only Vd ss showed a statistically significant difference between the 2 doses. The plasma level-time curves and pharmacokinetic parameters of ATRA obtained after oral administration of 1.60 mg kg -1 and 0.40 mg kg -1 are given in Figure 2 and Table 3 . Visual inspection of the plasma level-time curves and comparison of the T max values showed the absorption of ATRA to be slower in the case of administration of the higher dose. However, the normalized AUC was similar for both doses, thus indicating similar bioavailability. In fact, the bioavailability of each, estimated as the oral-to-IV AUC ratio, was 39% and 40%, respectively. The ATRA t 1/2 estimated after the oral ad- ministration of 1.60 mg kg -1 was similar to that observed after IV bolus administration (26 ± 3 minutes and 27 ± 4 minutes, respectively). However, the approximate t 1/2 value determined after the oral administration of 0.40 mg kg -1 was 2-fold greater (43 ± 15 minutes, Table 3 ). Nevertheless, this t 1/2 value was affected by the lack of experimental concentration-time data in the terminal phase of the curve (Figure 2) , which could not be obtained because the plasma concentration of ATRA was below the quantification limit of the analytical method employed; consequently, this t 1/2 value does not represent the "true" t 1/2 value corresponding to this kind of administration.
Two Consecutive Doses
The IV administration of a second dose of 1.60 mg kg -1 of ATRA 180 minutes after administration of the first dose gave rise to a plasma level-time profile different from that obtained after administration of a single dose (Figure 3) as only 2 phases were observed in the plasma vs time curve. After the initial fast decline of plasma levels (the first 3 points after second dose administration), a second phase with a slope similar to the slope of the third phase corresponding to a single dose was identified ( Figure 3) . The ATRA Cl after administration of the second dose was greater than the Cl obtained with a single dose ( Table 4) , thus indicating a faster elimination of ATRA after administration of the second dose. All these results point to time-dependent kinetics of ATRA rather than concentration-dependent kinetics.
The effect of the time-dependent kinetics is evident 180 minutes after administration of the first IV dose, giving rise to a faster elimination of ATRA. When 2 consecutive doses of ATRA were given orally, the plasma levels obtained after the second dose were much lower than those obtained with a single dose (Figure 4) . In fact, the AUC value corresponding to the second dose was only 8% of the AUC value obtained with a single dose ( Table 5 ). The decrease in AUC value corresponding to the second dose was more pronounced in the case of oral administration (92%) than with IV administration (30%). Mean plasma levels (± SD) of ATRA obtained after the oral administration of 2 consecutive doses of 1.60 mg kg -1 to the rats in group 6, the second dose being administered at 240 minutes. The plasma levels obtained with a single dose (group 3) are also indicated.
Intravenous Infusion of ATRA
The plasma level-time curve obtained during the 10 hours of the IV infusion of ATRA ( Figure 5) showed an increase in the plasma ATRA concentration during the first 180 minutes of infusion. However, after this time, the plasma ATRA concentration did not continue in- creasing to reach a steady-state drug concentration, as expected for an IV constant-rate infusion. Instead, a decrease in ATRA plasma concentration was observed, and a much lower apparent steady-state drug concentration was reached at 420 minutes. This result confirms the existence of time-dependent kinetics, leading to an increase in ATRA Cl 180 minutes after IV administration. The ATRA Cl, estimated as the ratio between constant-rate infusion and apparent steady-state plasma concentration (18.9 ± 4.7 mL min -1
), was ~7-fold greater than Cl obtained after the IV bolus injection of a single dose. 
Pharmacokinetic Model Fitting
Pharmacokinetic parameter values obtained after fitting of the proposed pharmacokinetic model to the plasma concentration-time data corresponding to rats IV dosed with ATRA (groups 1, 2, 5, and 7) are given in Table 6 . The graphic representation of the time-dependent clearance of ATRA is shown in Figure 6 together with the plasma ATRA concentrations predicted by the pharmacokinetic model. As can be seen, the model-predicted plasma concentrations of ATRA are in agreement with the observed concentrations. Figure 6 . Top, plot of ATRA clearance vs time obtained using the parameter values shown in . Bottom, mean plasma levels of ATRA after IV bolus administration or during IV constant-rate infusion (symbols), and modelpredicted concentrations (lines). The symbol key is the same as in Figures 1, 3 , and 5.
DISCUSSION
ATRA pharmacokinetics is complex, and the use of high doses could give rise to saturation of a capacity-limited elimination process described in rats, 19 monkeys, 20 and humans. 21 In such a case, the interpretation of the pharmacokinetic features of the drug could be difficult, since 2 opposite effects (time-dependent increased elimination and saturated elimination) would affect the plasma concentration-time curves. The doses used in this study do not seem high enough to saturate the elimination of ATRA (similar Cl value for the high and low dose, Table 2 ); therefore only time-dependent elimination was expected to be operative in our experiments or, at least, to predominate over the capacity-limited (saturable) elimination process.
This study shows the pharmacokinetics of ATRA in rats to be time dependent. After IV bolus administration or during IV constant-rate infusion, the time-dependent pharmacokinetics was observed very early, ~180 minutes after bolus administration or the start of infusion. Previous studies in humans reported time-dependent pharmacokinetics of ATRA attributed to induction of the ATRA elimination process; however, this effect-which can produce an 88% reduction in AUC-was studied after 3 or 7 days of multiple oral doses. 10, 11 Similarly, time-dependent ATRA kinetics has been recorded in the rat after 12 days of daily oral dosing, with a decrease in the AUC and volume of distribution values. 19 However, the results of the present study show that the decreases in AUC and Vd ss values of ATRA occur very early, since a second dose administered 180 minutes after the first one shows significantly lower values for these parameters (Table 4) .
Recently, it was reported that an ATRA-inductible CYP (CYP 26) increases to nearly 10-fold above control after 3 hours of ATRA administration in rats. 22 This result is consistent with that obtained in the present study; an increase in the elimination (clearance) of ATRA after 180 minutes of IV administration. Results obtained in rats in the present study seem similar to those recorded in monkeys subjected to IV injection of ATRA, 20 involving plasma disappearance of ATRA characterized by 3 distinct phases: a brief, initial exponential decline followed by a relative plateau in the disappearance curve (the duration of which was dose dependent), and finally, a terminal exponential decay. Although the authors interpreted this ATRA plasma-time profile as a capacitylimited (saturable) elimination process, it could also be interpreted as a time-dependent elimination process, as observed in the rat.
A compartmental pharmacokinetic model has been developed to describe ATRA disposition in the rat. The parameter values obtained after fitting the model to the experimental concentrations of ATRA (Table 6) show that the initial plasma clearance of ATRA (2.4 mL min ) is similar to clearance after a single IV dose (2.6-2.9 mL min -1 , Table 2 ), and maximum clearance (20 mL min -1 ) is similar to the clearance estimated as the ratio between constant-rate infusion and apparent steady-state plasma concentration in group 7 (18.9 mL min -1 ). The T lag value (191 minutes) is slightly greater than the value estimated from plots of the plasma level-time data (~180 minutes).
The absorption of ATRA after oral administration was slower for the highest dose. The cause of this slower absorption could be the precipitation of a higher proportion of ATRA in the stomach or intestine in the case of the highest dose. Another cause could be the existence of carrier-mediated transport. Nevertheless, the bioavailability of ATRA was similar for both orally administered doses (39% and 40%, respectively), thus indicating that while the underlying mechanism causes the ATRA absorption rate to decrease as the dose increases, it does not reduce the fraction of dose reaching the general circulation. In humans, ATRA bioavailability has been estimated to be ~50%, 12 although in a more recent study in healthy volunteers, the bioavailability of oral ATRA was estimated to be no more than 25% to 30%. 23 Therefore, the oral bioavailability of ATRA found in the rat is within the range observed in humans. The administration of a second oral dose of ATRA gave rise to an AUC reduction of 92% as compared with the AUC value after a single oral dose. This reduction is similar to that observed in humans (88%) after 7 days of continuous daily administration. 10 However, in the case of IV administration, the AUC reduction corresponding to the second dose was only 30%. This difference in AUC reduction depending on the administration route could be related to the difference in time elapsed between the first and the second administrations. After administration of the first dose, the second IV dose was administered at 180 minutes, while the second oral dose was administered at 240 minutes. The plasma concentration-time curve obtained during the infusion of ATRA shows that the decrease in plasma ATRA concentration starts at ~180 minutes but progresses until 420 minutes. Since the second oral dose was administered later than the second IV dose, it was subjected to a more intense reduction in plasma concentration than the second IV dose. In a recent study, it was observed that ATRA-metabolizing enzyme CYP26 was upregulated in intestinal cells after ATRA exposure, 24 and this effect could also explain the more pronounced AUC reduction after oral administration than after IV administration of the second dose.
Several strategies are now under investigation for either preventing the induction of accelerated ATRA elimination or overcoming it after onset. One strategy is the coadministration of inhibitors of the CYP enzyme oxidative system. Results obtained in the present study show that the rat may serve as a useful animal model for the in vivo preclinical studies of such inhibitors. For example, administration of potential inhibitors at the beginning or during a constant-rate infusion of ATRA would be a very simple and rapid method to evaluate the capacity of the inhibitors to avoid the decrease in plasma ATRA concentration observed after 180 minutes.
